FINANCIAL RESULTS
2022-04-28LL

First quarter 2022 results

First quarter 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Featuring

  • Paul Hudson
    Chief Executive Officer
  • Jean-Baptiste de Chatillon
    Chief Financial Officer
  • Bill Sibold
    Specialty Care
  • Olivier Charmeil
    General Medicines
  • John Reed
    R&D
  • Thomas Triomphe
    Vaccines
  • Julie van Ongevalle
    Consumer Healthcare
  • Roy Papatheodorou
    General Counsel

Highlights

"We’re off to a good start in 2022 thanks to a strong commitment to our strategy. We’re proud of the progress made in Immunology, with a broad pipeline of 13 potential new treatments in development."

Paul Hudson, CEO at Sanofi

Webinar

14:30 -16:00 CET | 8:30am – 10am EST

Contacts

Investor Relations
  investor.relations (at) sanofi.com 
  More contact information